Download presentation
Presentation is loading. Please wait.
Published byMarco Figueiroa Modified over 5 years ago
1
E2F4 program is predictive of the efficacy of intravesical BCG immunotherapy in NMIBC. A, the survival curves of intravesical therapy-treated and untreated groups are compared all in A, E2F4>0 (B), and E2F4<0 NMIBC samples (C). E2F4 program is predictive of the efficacy of intravesical BCG immunotherapy in NMIBC. A, the survival curves of intravesical therapy-treated and untreated groups are compared all in A, E2F4>0 (B), and E2F4<0 NMIBC samples (C). IVT: intravesical BCG immunotherapy. Chao Cheng et al. Mol Cancer Res 2015;13: ©2015 by American Association for Cancer Research
Similar presentations
© 2025 SlidePlayer.com. Inc.
All rights reserved.